Stock listing
170900 Stock Price, News, Filings & Events — Dong-a St Co., Ltd.
Selected listing: 170900 · KRX · KRW · KR
This page tracks Dong-a St Co., Ltd.'s 170900:KRX listing on KRX in KRW for KR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 170900:KRX. 170900:KRX is the stock-level entry point for investors researching Dong-a St Co., Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Dong-a St Co., Ltd. is a publicly traded company on the Korean market, identified by the ticker 170900. The company has a market capitalization of approximately 230.3 billion KRW. Dong-a St Co., Ltd. focuses on providing high-quality products and services within its industry.
- Ticker
- 170900:KRX
- Asset type
- Stock
- Market cap
- $243.6M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- KRX
- Currency
- KRW
Dong-a St Co., Ltd. 170900:KRX stock context
This page tracks Dong-a St Co., Ltd.'s 170900:KRX listing on KRX in KRW for KR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 170900:KRX. 170900:KRX is the stock-level entry point for investors researching Dong-a St Co., Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Dong-a St Co., Ltd. is a publicly traded company on the Korean market, identified by the ticker 170900. The company has a market capitalization of approximately 230.3 billion KRW. Dong-a St Co., Ltd. focuses on providing high-quality products and services within its industry.
Latest news from Dong-a St Co., Ltd.
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
March 12, 2026
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
February 13, 2026
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
August 19, 2025
Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®, receives approval from US FDA
October 14, 2024
Dong-A ST Out License NESP® Biosimilar DA-3880 to Polifarma of Türkiye
November 9, 2022